Literature DB >> 6178461

Impact of maternal serum alpha-fetoprotein screening on antenatal diagnosis.

D J Brock.   

Abstract

An analysis has been made of indications for amniocentesis in the Edinburgh area from 1979 to 1981. About 5% of all mothers underwent the procedure. Among 2137 amniocenteses, 37% were performed on mothers 35 years old or more, and 30% on patients with raised serum alpha-fetoprotein. The total number of amniocenteses and the categories have been stable for the past three years. As a result of amniocentesis 104 pregnancies were terminated, 66 of which (63%) followed a raised maternal serum alpha-fetoprotein indication, while only 10 (9.6%) were in mothers aged 35 or more. There were a further 12 terminations based on raised serum alpha-fetoprotein but where no amniocentesis had been thought necessary. Even when figures for anencephaly are excluded from the analysis, maternal serum alpha-fetoprotein screening was responsible for detecting 35 out of 63 (56%) abnormal fetuses. This constitutes a strong case for the continuation of alpha-fetoprotein screening programmes.

Entities:  

Keywords:  Empirical Approach; Genetics and Reproduction; Health Care and Public Health

Mesh:

Substances:

Year:  1982        PMID: 6178461      PMCID: PMC1498988          DOI: 10.1136/bmj.285.6338.365

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  9 in total

1.  Genetic counseling for the older pregnant woman: new data and questions.

Authors:  L B Holmes
Journal:  N Engl J Med       Date:  1978-06-22       Impact factor: 91.245

Review 2.  New uncertainties in prenatal screening for neural tube defect.

Authors:  R Harris; A P Read
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-02

3.  Vitamin supplementation and neural tube defects.

Authors: 
Journal:  Lancet       Date:  1982-01-30       Impact factor: 79.321

4.  19-year incidence of neural tube defects in area under constant surveillance.

Authors:  J R Owens; F Harris; E McAllister; L West
Journal:  Lancet       Date:  1981-11-07       Impact factor: 79.321

5.  Restriction enzyme analysis of herpesvirus-2 DNA.

Authors:  I W Smith; N J Maitland; J F Peutherer; D H Robertson
Journal:  Lancet       Date:  1981 Dec 19-26       Impact factor: 79.321

6.  Maternal alpha-fetoprotein screening: two years' experience in a low-risk district.

Authors:  S J Standing; M J Brindle; A P Macdonald; R W Lacey
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-12

7.  Screening for neural-tube defects and maternal anxiety.

Authors:  J Fearn; B M Hibbard; K M Laurence; A Roberts; J O Robinson
Journal:  Br J Obstet Gynaecol       Date:  1982-03

8.  Maternal plasma alpha-fetoprotein screening for fetal neural tube defects.

Authors:  D J Brock; J B Scrimgeour; J Steven; L Barron; M Watt
Journal:  Br J Obstet Gynaecol       Date:  1978-08

9.  Significance of elevated mid-trimester maternal plasma-alpha-fetoprotein values.

Authors:  D J Brock; L Barron; P Duncan; J B Scrimgeour; M Watt
Journal:  Lancet       Date:  1979-06-16       Impact factor: 79.321

  9 in total
  4 in total

1.  Semiquantitative determination of α-fetoprotein in the noninstrumental immunoassay system.

Authors:  M B Raev; M S Bochkova
Journal:  Dokl Biol Sci       Date:  2012-07-05

2.  Maternal serum alpha-fetoprotein screening for neural tube defects. Report of a combined study in Germany and short overview on screening in populations with low birth prevalence of neural tube defects.

Authors:  W Fuhrmann; H K Weitzel
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

Review 3.  Clinical biochemistry of the neonatal period: immaturity, hypoxia, and metabolic disease.

Authors:  R A Harkness
Journal:  J Clin Pathol       Date:  1987-09       Impact factor: 3.411

4.  Ethical problems.

Authors:  R W Smithells
Journal:  Arch Dis Child       Date:  1982-12       Impact factor: 3.791

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.